#PCV20
PCV21 (V116) contains 8 serotypes not included in the other available pneumococcus vaccines.

ACIP recommended 21-valent PCV (PCV21) as an option for adults aged ≥19 years who recommended to receive PCV15 or PCV20 as it is expected to prevent additional dz. #IDSky

academic.oup.com/cid/advance-...
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Ag...
This article describes results of a phase 3 study assessing the safety, tolerability, and immunogenicity of 21-valent pneumococcal conjugate vaccine, V116,
academic.oup.com
November 11, 2025 at 3:21 PM
I just got myself vaccinated for COVID, the flu & PCV20 because I care about my health & the health of everyone around me. ✔️
November 6, 2025 at 4:49 AM
Nee nu niet meer elke 5 jaar. Vanaf 2025 wordt er veelal geprikt met nieuwe variant vaccin PCV20 .
Dit vaccin is effectiever tegen het voorkomen van (ernstige) pneumokokkenziekte en hoeft bovendien slechts één keer te worden toegediend, in plaats van iedere 5 jaar.
November 3, 2025 at 2:29 PM
ICYMI #IDWeek #IDSky

Lymphoma survivors randomized to 1 or 2 doses of PCV20, then had a response checked at 3 months. Only serotype 3 (one of the more common serotypes) had significantly higher IgG response at 3 months.

www.pharmacytimes.com/view/two-dos...
Two Doses of PCV20 in Lymphoma Survivors Elicits Greater Humoral Response | Pharmacy Times
New research highlights the enhanced humoral response in lymphoma survivors receiving two doses of the PCV20 vaccine, emphasizing vaccination's critical role in infection prevention.
www.pharmacytimes.com
October 23, 2025 at 10:05 PM
Higher-valent #pneumococcal vaccines, PCV20 and PCV21, address shifting serotype patterns in adult invasive pneumococcal disease serotypes; vaccine choice depends on regional strain prevalence. ja.ma/4nf3fkK
October 22, 2025 at 2:28 PM
#IDsky
serotype distribution & resistance prior to pcv 20/21
- non bacteremic hospitalized episodes of pneumococcus have a different serotype distribution and tend to have higher resistance than IPD
- interesting breakdown on differences bw what pcv20 vs 21 would cover if vaccinated
October 21, 2025 at 4:40 PM
Guidelines now favor at least one conjugate dose for better long-term protection.
✅ One shot is enough if it was PCV20.
✅ If she got PCV15, she needs two total (PCV15 + PPSV23).
✅ If she’s not sure which she received, her clinician or pharmacy can check records.
Hope this helps :)
October 18, 2025 at 2:55 PM
If your mom got Prevnar 20 (PCV20) at age 68, she’s done that’s a single dose for life.
1. If she got Prevnar 15 (PCV15), she should get one PPSV23 dose at least a year later.
2. If she only ever got PPSV23, she may still benefit from a conjugate vaccine (PCV15 or PCV20).
October 18, 2025 at 2:55 PM
Great question ,this confuses a lot of people because pneumonia vaccines changed in recent years. There are two main types:
PCV (pneumococcal conjugate vaccine) e.g: Prevnar 20 (PCV20) or Prevnar 15 (PCV15)
PPSV23 (Pneumovax 23)- the older polysaccharide vaccine.
October 18, 2025 at 2:55 PM
Wichtiger Hinweis. Eine Pneumokokkenimpfung ist daher dringend empfohlen. Sie reduziert die Wahrscheinlichkeit von schweren invasiven Infektionen und rettet Leben. sprechen sie mit ihrem Arzt / ihrer Ärztin über diese wichtige Prävention. Impfquoten in Deutschland sind sehr niedrig. #PCV20
Pneumokokkeninfektionen sind bei Menschen mit HIV häufig, selbst bei höheren CD4-Zellzahlen. Impfung und HIV-Therapie verringern das Risiko einer invasiven Erkrankung. Eine Pneumokokken-Erkrankung wird mit Antibiotika behandelt. Leichte Fälle klingen in der Regel nach einigen Tagen ab.
Pneumococcal infections are common in people living with HIV. Symptoms of pneumococcal disease include fever, chills & sweats, headache, cough & a general feeling of being unwell. Mild cases are likely to go away after a few days.
October 1, 2025 at 10:43 AM
While the vaccine led to a decrease in the strains it covers, there was an increase in the prevalence of non-vaccine serotypes, which are included in newer vaccines like PCV13 and PCV20. #immunization #pneumococcal

Read More: bit.ly/4pDA3q0
Introduction of PCV10 Reduces Vaccine-Type Pneumococcal Strains
Further, after the introduction of the pneumococcal conjugate vaccine 10, investigators note a decrease of infections caused by multidrug resistance infection.
bit.ly
September 25, 2025 at 1:13 PM
It’s not 80.
CDC vaccination schedule as of last year through 15 months. I count 13, and not all are recommended for all patients.
September 22, 2025 at 10:15 PM
there is a lifetime pneumonia vax also a single dose of the 20-valent conjugate vaccine (Prevnar 20 or PCV20) generally providing life-long protection for adults. Ask for Prev20. The twenty indicates how many years AVERAGE MINIMUM it protects you.
August 25, 2025 at 5:38 PM
Studies show that PCV20 and PCV21 are generally safe & non-inferior in immunogenicity to PPSV23 for shared serotypes. Co-administration with influenza or #COVID19vaccines is also safe & effective, though it may increase mild systemic side effects like headaches , muscle pain.
August 21, 2025 at 6:39 PM
The transition from PPSV23 to PCV20/PCV21 doesn’t hinder the simultaneous administration of COVID, Flu & Pneumococcus vaccines. In fact, it may simplify vaccination schedules.
August 21, 2025 at 6:38 PM
I guess I meant in terms of whether the PPSV23 phaseout in favor of PCV20/PCV21 affects the ability to co-administer COVID+Flu+Pneumococcus vaccines (differential immunogenicity for PPSV vs. PCV)?
August 21, 2025 at 5:11 PM
In my understanding, based on the above studies, the shift away from PPSV23 towards PCV20/PCV21 represents a +ve steps in improving adult pneumococcal vaccination strategies, offering broader protection & simplifying vaccination schedules together with #COVID19 , #FluVaccines
August 20, 2025 at 8:10 PM
The phasing out of PPSV23 in favour of PCV20 or PCV21 is part of a broader shift towards conjugate vaccines for adult pneumococcal vaccination. This change is driven by the superior immunogenicity and broader serotype coverage of conjugate vaccines PCV20 & PCV21 vs the polysaccharide-based PPSV23.
August 20, 2025 at 8:03 PM
I wonder how the phase out of PPSV23 in favor of PCV20/PCV21 would affect this...
August 20, 2025 at 7:32 PM
Die STIKO hat in Sachen Pneumokokken-Impfung bei Neugeborenen entschieden. Sie empfiehlt weiterhin bei Reifgeborenen den PCV13- oder PCV15-Impfstoff im 2+1-Schema, bei Frühchen im 3+1-Schema. Es wird also NICHT der neue PCV20 empfohlen, der in anderen Altersklassen 1/3

www.rki.de/DE/Aktuelles...
www.rki.de
August 16, 2025 at 7:44 AM
Lookup Pneumococcal conjugate vaccines (PCVs), which include PCV15, PCV20, PCV21. It’s multi faceted, especially since the new research revelations on long Covid correlation with cancer.
August 8, 2025 at 11:36 PM
3 yrs post-vaccination, seroprotection rates dropped: PLWH 44%➡️9%, immunosuppressive therapy 55%➡️17%, controls 82%➡️42%. Rapid recall: PLWH 40%, controls 67%. Future focus on PCV20.##idsky
Long-term immunogenicity and boostability of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in adults receiving immunosuppressive therapy and adults living with HIV – 3-year follow-up of a prospective cohort study
AbstractIntroductionThSABSe long-term immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13), followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) remains unclear among immunocompromised patients (ICPs).MethodsThis three-year follow-up of a previously reported prospective cohort study included people living with HIV (PLWH), patients on immunosuppressive therapy, and immunocompetent controls who received PCV13 followed by PPSV23 two months later. IgG levels for all 24 vaccine serotypes were measured three years after PCV13 (M36). The primary outcome was the seroprotection rate (SPR) at M36, defined as IgG concentrations ≥1.3 μg/mL for 17/24 vaccine serotypes. To assess immunological memory, we measured rapid recall responses seven days after a PCV20 booster vaccination among initial responders two months after the priming schedule (M4) who had sero-reverted at M36.ResultsBetween M4 to M36, SPRs dropped from 44% (22/50) to 9% (5/55) in PLWH, from 55% (59/108) to 17% (22/131) in patients on immunosuppressive therapy and from 82% (14/17) to 42% (8/19) in controls. Rapid recall responses were observed in 40% (4/10) of PLWH, 14% (2/14) of patients on immunosuppressive monotherapy, 22% (2/9) of patients on combination therapy, and 67% (2/3) of controls. Antibody levels increased significantly for 7/13 PCV20/PCV13-shared serotypes, but for none (0/7) of the PCV20/PPSV23-shared serotypes.ConclusionsOnly a minority of PLWH and patients on immunosuppressive therapy and under half of controls remained seroprotected three years after vaccination. As rapid recall responses were limited to PCV serotypes, future research in ICPs should focus on expanded priming schedule with higher-valent PCVs such as PCV20.
academic.oup.com
August 6, 2025 at 4:30 PM
Ось перелік показів до вакцинації з Інституту Роберта Коха www.rki.de/EN/Topics/In...
August 2, 2025 at 7:08 PM